Clinical trials: Early Diagnosis
Vaginal Atrophy
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in…
- Trial name
- BLISSAFE (NCT02413008)
- Testing
- estriol
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 61 people
- Sponsor
- ITF Research Pharma, S.L.U.
Pregnancy, Early Detection
Sofia hCG FIA Field Study
The objective of this field study is to demonstrate the clinical performance of the Sofia hCG FIA Test, using urine specimens from females of childbearing age.
- Trial name
- NCT01803113
- Testing
- Sofia hCG FIA
- Where
- 5 sites in United States
- Volunteers
- 975 people
- Sponsor
- Quidel Corporation
Neoplasms, Breast
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole
- Trial name
- NCT00422903
- Testing
- lapatinib, letrozole
- Where
- 14 sites in Italy, Spain
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Colonoscopy, Colorectal Cancer Screening
Triton 1.5 Robotic System for Diagnostic Colonoscopy in the Middle East
The purpose of this study is to gain early experience in the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤ 2 cm).
- Trial name
- CARE-UAE (NCT07835542)
- Testing
- Diagnostic Test: Diagnostic Colonoscopy
- Where
- United Arab Emirates
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Neptune Medical
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03743285
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Natural History Study: ENPP1 Deficiency or the Early-Onset Form of ABCC6 Deficiency
The purpose of this study is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency and the early-onset form of adenosine triphosphate binding cassette transporter subfamily C…
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Generalized Arterial Calcification of Infancy, Autosomal Recessive Hypophosphatemic Rickets
- Trial name
- NCT07745179
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 23 people
- Sponsor
- Inozyme Pharma
Alzheimer's Disease
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy…
- Trial name
- NCT01767311
- Testing
- Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg
- Where
- 169 sites in United States, Canada and 9 more
- Volunteers
- 856 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort.
- Trial name
- NCT04437511
- Testing
- Donanemab
- Where
- 274 sites in United States, Australia and 7 more
- Volunteers
- 1,736 people
- Sponsor
- Eli Lilly and Company
Neoplasms, Breast
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
- Trial name
- CHERLOB (NCT00429299)
- Testing
- lapatinib, trastuzumab, paclitaxel
- Where
- 17 sites in Germany, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Syphilis Infection, Syphilis
Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT
This study is to test the Reveal® TP (Syphilis) antibody POCT (MedMira, Inc., Halifax, Nova Scotia) for its performance in an urban STI clinic in Vancouver, British Columbia and compare its performance in parallel with the usual…
- Conditions
- Syphilis Infection, Syphilis, Early Syphilis, Symptomatic
- Trial name
- NCT05831098
- Testing
- Reveal TP (Syphilis) Antibody Test
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
Coronary Artery Disease
Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG
Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery.
- Trial name
- NCT06150872
- Testing
- DurVena Photochemical Tissue Passivation
- Where
- Uzbekistan
- Volunteers
- 4 people
- Sponsor
- DurVena, Inc.
B-cell Chronic Lymphocytic Leukemia
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to provide early access to Ibrutinib treatment for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and collect additional safety data while the medication is not…
- Trial name
- NCT02437019
- Testing
- PCI-32765 (Ibrutinib)
- Where
- 6 sites in Brazil
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Rheumatoid Arthritis
A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis
This is a randomized, open label, active-comparator, parallel design, outpatient, multicenter study being conducted in Mexico. Subjects with early active Rheumatoid Arthritis (RA) who have not received treatment with a…
- Trial name
- DOTAR (NCT00783536)
- Testing
- Etanercept + Methotrexate, DMARDS
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer of the Pancreas, Pancreatic Cancer
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired…
- Conditions
- Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I
- Trial name
- VERIFI (NCT06947395)
- Testing
- PancreaSure
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Immunovia, Inc.
Breast Neoplasms
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms…
- Trial name
- IES (NCT00038467)
- Testing
- Tamoxifen, Exemestane
- Where
- 377 sites in United States, Argentina and 35 more
- Volunteers
- 4,740 people
- Sponsor
- Pfizer
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.